Johnson & Johnson announced the submission of a supplemental New Drug Application to the U.S. FDA seeking approval of SPRAVATO CIII nasal spray as a monotherapy for adults living with treatment-resistant depression. Nearly 30% of the estimated 280M people worldwide living with major depressive disorder have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $155 from $160 at Goldman Sachs
- Johnson & Johnson price target lowered to $185 from $195 at TD Cowen
- Johnson & Johnson price target raised to $169 from $167 at Morgan Stanley
- Stock Market News Today, 7/17/24 – Nasdaq Sinks Almost 3%; Housing Data Beats Estimates
- Johnson & Johnson price target raised to $160 from $155 at Stifel